about
Selection platforms for directed evolution in synthetic biologyA lncRNA Perspective into (Re)Building the HeartAntisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse.Polypurine reverse-Hoogsteen (PPRH) oligonucleotides can form triplexes with their target sequences even under conditions where they fold into G-quadruplexes.Monitoring integrity and localization of modified single-stranded RNA oligonucleotides using ultrasensitive fluorescence methods.Lipophilic 2'-O-Acetal Ester RNAs: Synthesis, Thermal Duplex Stability, Nuclease Resistance, Cellular Uptake, and siRNA Activity after Spontaneous Naked Delivery.Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide.Nucleic Acid Templated Reactions for Chemical Biology.Targeted protein knockdown using small molecule degraders.Gapmer Antisense Oligonucleotides Suppress the Mutant Allele of COL6A3 and Restore Functional Protein in Ullrich Muscular Dystrophy.LNA effects on DNA binding and conformation: from single strand to duplex and triplex structuresThe novel functional nucleic acid iRed effectively regulates target genes following cytoplasmic delivery by faint electric treatment.CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression.Influenza virus segment 5 (+)RNA - secondary structure and new targets for antiviral strategies.Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing.As Technologies for Nucleotide Therapeutics Mature, Products Emerge.Zinc Ion-Dependent Peptide Nucleic Acid-Based Artificial Enzyme that Cleaves RNA-Bulge Size and Sequence Dependence.Emerging roles of RNA-binding proteins in diabetes and their therapeutic potential in diabetic complications.Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ.miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating FAS Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases.Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies.Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and d-altritol nucleic acid-modified 2'-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro.Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma.The development of ruthenium(ii) polypyridyl complexes and conjugates for in vitro cellular and in vivo applications.RNA-directed off/on switch of RNase H activity using boronic ester formation.Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction.Stimuli-responsive oligonucleotides in prodrug-based approaches for gene silencing.Artificial cationic oligosaccharides for heteroduplex oligonucleotide-type drugs.Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo.Targeting MIR155HG in glioma: a novel approach.Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain.Antisense oligonucleotides in neurological disorders.RBPs Play Important Roles in Vascular Endothelial Dysfunction Under Diabetic ConditionsDetection of phosphorothioated (PS) oligonucleotides in horse plasma using a product ion (m/z 94.9362) derived from the PS moiety for doping control
P2860
Q26741325-C9C3EC87-A0B2-41A1-93B6-EA730740B80BQ28066790-629BACF5-BC41-4BE8-8F22-1BDD6F0C932EQ30832682-EB8A628F-98B8-44C1-8B5A-C0B9FF6C4567Q36244171-F8F991A4-999F-48C5-BE7A-5D230F60D51EQ36302402-560B1385-B68B-433E-B49C-1463C11E47A4Q38734379-29B85732-16D4-4A35-BBB1-3E7508F9F3BFQ38734734-EF9D5C82-E7B9-4E4A-9600-E09C8212843EQ39159171-D6FDF778-CF0E-4876-B3C2-D5403159743AQ39290375-307A1C8A-07F6-4CDF-B3DA-79A5506E1E38Q39367115-BDF5BE9F-8F23-469B-91CD-44BC39D4FBF7Q41191227-F90B40F0-4AA1-44F8-A62A-78A686EA65E9Q41478215-DC318DBA-0096-4CBC-B9EF-D0B86AD3CA81Q41872943-425B815C-2292-4355-8C5D-C7FC0ECC3026Q42258984-B26EC528-304A-4550-A1B1-18D81D26F7ACQ45325101-60F1BD88-B5AD-439C-A1B9-8096FFB3E8D0Q45869092-FA6560F3-49A0-4B1E-8F49-B1267E4C0F9AQ47131796-D9059629-3648-4686-9FB4-1BE76B0A8DDEQ47177698-BB69DFAA-EAC5-435B-B7B0-A3611921C5F4Q47252604-646524EC-6D61-433C-95EE-650D2BC7CA27Q47569463-A53FD26B-EA11-4BF3-A463-4CCBFF696E76Q47606680-E60DCF76-D0C2-4024-8FB0-BA58CF645B13Q47699115-92761A44-4AAE-447C-A29F-2B9BDC404FEBQ48692478-277104F1-2A09-4DBE-B8BE-C33F12FED505Q48952319-3B293172-F1F3-4E66-B52F-0A8D3B81E17BQ49163466-472A39BB-CFA8-4EBF-8F3F-33642F42DA17Q49611544-C423E951-4059-4029-B79F-652CB83755C4Q50022117-8D5259B3-E70F-435A-9026-B5987C67099DQ50075192-0E2FFAB2-B14E-496F-89B0-3EDBB8D0354FQ51742560-A268B045-8CB1-4163-8C9E-51176B2F90F4Q52659449-5852101E-4F38-4892-B11A-0C1A5FA6895CQ52659503-C022104C-8864-4776-9BA2-2A5D4FA1C39BQ53105313-0DB7A536-4D04-4DFC-9166-39DE47AF7658Q54974399-939B4A0D-22AE-4086-BF74-8CBEC04F13E7Q55018458-CB6766AF-11F2-4EDC-8137-74D23F49ECF2Q57191813-76A1032C-C45D-495E-A6DA-4C8BEBA266DCQ58101365-319703F1-5725-4694-9F4A-08D5E41EB1E3
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Oligonucleotide Therapies: The Past and the Present
@ast
Oligonucleotide Therapies: The Past and the Present
@en
Oligonucleotide Therapies: The Past and the Present
@nl
type
label
Oligonucleotide Therapies: The Past and the Present
@ast
Oligonucleotide Therapies: The Past and the Present
@en
Oligonucleotide Therapies: The Past and the Present
@nl
prefLabel
Oligonucleotide Therapies: The Past and the Present
@ast
Oligonucleotide Therapies: The Past and the Present
@en
Oligonucleotide Therapies: The Past and the Present
@nl
P2860
P3181
P356
P1433
P1476
Oligonucleotide Therapies: The Past and the Present
@en
P2093
Karin E Lundin
P2860
P304
P3181
P356
10.1089/HUM.2015.070
P407
P577
2015-08-03T00:00:00Z